CN109152777A - 疼痛的治疗 - Google Patents

疼痛的治疗 Download PDF

Info

Publication number
CN109152777A
CN109152777A CN201780031175.0A CN201780031175A CN109152777A CN 109152777 A CN109152777 A CN 109152777A CN 201780031175 A CN201780031175 A CN 201780031175A CN 109152777 A CN109152777 A CN 109152777A
Authority
CN
China
Prior art keywords
compound
par
signaling
formula
endosomal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780031175.0A
Other languages
English (en)
Chinese (zh)
Inventor
N.邦尼特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2016901912A external-priority patent/AU2016901912A0/en
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of CN109152777A publication Critical patent/CN109152777A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Botany (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
CN201780031175.0A 2016-05-20 2017-05-19 疼痛的治疗 Pending CN109152777A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2016901912 2016-05-20
AU2016901912A AU2016901912A0 (en) 2016-05-20 Treatment of Pain
PCT/AU2017/050469 WO2017197463A1 (en) 2016-05-20 2017-05-19 Treatment of pain

Publications (1)

Publication Number Publication Date
CN109152777A true CN109152777A (zh) 2019-01-04

Family

ID=60324618

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780031175.0A Pending CN109152777A (zh) 2016-05-20 2017-05-19 疼痛的治疗

Country Status (9)

Country Link
US (1) US20190298743A1 (https=)
EP (1) EP3458062A4 (https=)
JP (3) JP2019516734A (https=)
CN (1) CN109152777A (https=)
AU (3) AU2017268039A1 (https=)
CA (1) CA3024719A1 (https=)
EA (1) EA201892672A1 (https=)
MX (2) MX395658B (https=)
WO (1) WO2017197463A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA202091524A1 (ru) * 2017-12-20 2020-09-16 Такеда Фармасьютикал Компани Лимитед Ингибиторы рецептора, активируемого протеазой 2
US20240066027A1 (en) 2020-12-03 2024-02-29 Domain Therapeutics Novel par-2 inhibitors
KR20250057699A (ko) 2022-06-03 2025-04-29 도메인 테라퓨틱스 신규한 par-2 억제제
WO2025172573A1 (en) 2024-02-16 2025-08-21 Domain Therapeutics Combinations of par2 inhibitors and immune checkpoint inhibitors for the treatment of cancer
WO2025191185A1 (en) 2024-03-15 2025-09-18 Domain Therapeutics Azine-based compounds as par-2 inhibitors and therapeutic uses thereof

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994006450A1 (en) * 1992-09-17 1994-03-31 Universtiy Of Florida Brain-enhanced delivery of neuroactive peptides by sequential metabolism
WO2005097199A1 (en) * 2004-04-08 2005-10-20 Jadolabs Gmbh Tripartite conjugates containing a structure interacting with cell membrane rafts and their use
CN1938013A (zh) * 2003-11-21 2007-03-28 纽卡斯尔大学研究协会有限公司 抑制发动蛋白依赖性的细胞内摄作用的方法和药剂
WO2009034464A2 (en) * 2007-09-12 2009-03-19 Newcastle Innovation Limited Indole related compounds with physiological activity
US7541156B1 (en) * 2000-03-01 2009-06-02 Pasricha Pankaj J Method of identifying antinociceptive compounds using protease activated receptor-2
WO2009117481A1 (en) * 2008-03-19 2009-09-24 Regeneron Pharmaceuticals, Inc. Use of protease-activated receptor 2 antagonists
WO2013010218A1 (en) * 2011-07-15 2013-01-24 Freie Universität Berlin Inhibition of clathrin
WO2015048245A1 (en) * 2013-09-25 2015-04-02 Vertex Pharmaceuticals Incorporated Imidazopyridazines useful as inhibitors of the par-2 signaling pathway
WO2017112972A1 (de) * 2015-12-30 2017-07-06 Technische Universität Wien Verfahren zur herstellung von ionischen flüssigkeiten
WO2019124567A1 (en) * 2017-12-20 2019-06-27 Takeda Pharmaceutical Company Limited Inhibitors of protease activated receptor-2

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070225363A1 (en) * 2003-11-21 2007-09-27 The University Of Newcastle Research Associates Ltd. Methods and Agents for Inhibiting Dynamin-Dependent Endocytosis
JP4896870B2 (ja) * 2004-04-08 2012-03-14 ヤード・テヒノロギース・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 細胞膜ラフトと相互作用する構造を含む三者複合体およびその使用
CN115531553A (zh) * 2015-12-22 2022-12-30 武田药品工业株式会社 内体g蛋白-偶联的受体的三部分调节剂

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994006450A1 (en) * 1992-09-17 1994-03-31 Universtiy Of Florida Brain-enhanced delivery of neuroactive peptides by sequential metabolism
US7541156B1 (en) * 2000-03-01 2009-06-02 Pasricha Pankaj J Method of identifying antinociceptive compounds using protease activated receptor-2
CN1938013A (zh) * 2003-11-21 2007-03-28 纽卡斯尔大学研究协会有限公司 抑制发动蛋白依赖性的细胞内摄作用的方法和药剂
WO2005097199A1 (en) * 2004-04-08 2005-10-20 Jadolabs Gmbh Tripartite conjugates containing a structure interacting with cell membrane rafts and their use
WO2009034464A2 (en) * 2007-09-12 2009-03-19 Newcastle Innovation Limited Indole related compounds with physiological activity
WO2009117481A1 (en) * 2008-03-19 2009-09-24 Regeneron Pharmaceuticals, Inc. Use of protease-activated receptor 2 antagonists
WO2013010218A1 (en) * 2011-07-15 2013-01-24 Freie Universität Berlin Inhibition of clathrin
WO2015048245A1 (en) * 2013-09-25 2015-04-02 Vertex Pharmaceuticals Incorporated Imidazopyridazines useful as inhibitors of the par-2 signaling pathway
WO2017112972A1 (de) * 2015-12-30 2017-07-06 Technische Universität Wien Verfahren zur herstellung von ionischen flüssigkeiten
WO2019124567A1 (en) * 2017-12-20 2019-06-27 Takeda Pharmaceutical Company Limited Inhibitors of protease activated receptor-2

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ANDREA N. FLYNN等: "Development of highly potent protease-activated receptor 2 agonists via synthetic lipid tethering", 《THE FASEB JOURNAL》 *
PEISHEN ZHAO等: "Protease-Activated Receptor 2 Signals from Endosomes to Control Sensitivity", 《GASTROENTEROLOGY》 *
SCOTT BOITANO等: "Potent lipidated antagonists to protease-activated receptor 2 (PAR2)", 《THE FASEB JOURNAL》 *

Also Published As

Publication number Publication date
JP2022061998A (ja) 2022-04-19
NZ788380A (en) 2025-07-25
EP3458062A1 (en) 2019-03-27
JP7441246B2 (ja) 2024-02-29
JP2024073450A (ja) 2024-05-29
MX395658B (es) 2025-03-26
AU2023201732A1 (en) 2023-04-20
JP2019516734A (ja) 2019-06-20
EP3458062A4 (en) 2020-01-15
CA3024719A1 (en) 2017-11-23
MX2022011564A (es) 2023-06-15
EA201892672A1 (ru) 2019-04-30
AU2025202933A1 (en) 2025-05-15
NZ748579A (en) 2025-07-25
AU2017268039A1 (en) 2018-12-06
MX2018014135A (es) 2019-06-17
US20190298743A1 (en) 2019-10-03
WO2017197463A1 (en) 2017-11-23

Similar Documents

Publication Publication Date Title
CN109152777A (zh) 疼痛的治疗
US8552050B2 (en) Activators of pyruvate kinase M2 and methods of treating disease
US20230119819A1 (en) Tripartite Modulators of Endosomal G Protein-Coupled Receptors
JP2025041721A (ja) Ｐｐ２ａアンカリングの阻害による心疾患の処置
US7625718B2 (en) SVCT2 transporters expressed in blood brain barrier cells
US7462459B2 (en) LAT1 transporters expressed in blood brain barrier cells
US20050170391A1 (en) TAUT1 transporters expressed in blood brain barrier cells
US7700300B2 (en) Screening of compounds for GAT2 transporter activity
US7691584B2 (en) Screening of compounds for OCT3 transporter activity
US7670782B2 (en) Screening of compounds for CAT1 transporter activity
US7704695B2 (en) Screening of compounds for BGT1 transporter activity
US7704696B2 (en) Screening of compounds for OCTN2 transporter activity
US20050170393A1 (en) OATPB transporters expressed in blood brain barrier cells
BR112018012425B1 (pt) Composto tripartido, e, composição farmacêutica

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination